NantHealth Inc (NYSE:NH) COO Ronald Allen Louks sold 26,820 shares of the company’s stock in a transaction dated Friday, October 6th. The shares were sold at an average price of $4.28, for a total transaction of $114,789.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of NantHealth Inc (NYSE:NH) opened at 4.02 on Wednesday. The stock’s market cap is $490.22 million. The company’s 50-day moving average is $4.44 and its 200 day moving average is $4.44. NantHealth Inc has a 52 week low of $3.96 and a 52 week high of $13.80.
NantHealth (NYSE:NH) last posted its earnings results on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The business had revenue of $26.23 million for the quarter, compared to analysts’ expectations of $31.28 million. During the same quarter last year, the business posted ($0.15) earnings per share. The business’s revenue was down 16.7% compared to the same quarter last year. Analysts forecast that NantHealth Inc will post ($0.70) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/10/11/nanthealth-inc-nh-coo-ronald-allen-louks-sells-26820-shares.html.
A number of large investors have recently bought and sold shares of the business. TIAA CREF Investment Management LLC increased its holdings in NantHealth by 68.6% during the 1st quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after acquiring an additional 8,217 shares in the last quarter. California State Teachers Retirement System increased its holdings in NantHealth by 132.4% during the 2nd quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock valued at $134,000 after acquiring an additional 18,000 shares in the last quarter. Bank of America Corp DE increased its holdings in NantHealth by 366.4% during the 1st quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock valued at $125,000 after acquiring an additional 19,694 shares in the last quarter. Alliancebernstein L.P. purchased a new position in NantHealth during the 2nd quarter valued at about $102,000. Finally, Teachers Advisors LLC increased its holdings in NantHealth by 351.8% during the 2nd quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after acquiring an additional 24,588 shares in the last quarter.
Several analysts recently issued reports on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $5.50 price objective (down previously from $8.00) on shares of NantHealth in a research note on Monday, June 19th. BidaskClub raised shares of NantHealth from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price objective (down previously from $8.00) on shares of NantHealth in a research note on Monday, August 21st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.25.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.